TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$40 Million

Humacyte, Inc.

Follow-on Offering

Lead Left Bookrunner, February 2024

Humacyte, Inc.

Humacyte, Inc. (“Humacyte”) (NASDAQ: HUMA) is pioneering the development and manufacture of off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. Humacyte is leveraging its novel, scalable technology platform to develop proprietary, bioengineered, acellular human tissues for use in the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.